Vertex Pharmaceuticals stock: Management's UBS conference appearance
Published on 11/16/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSConference schedule sets near-term focus
- Vertex management was scheduled to take part in a UBS Global Biopharma Conference fireside chat on November 16.
- A second investor-conference appearance is scheduled for November 17.
- The company says live webcasts and replays are available through its investor website.
Vertex Pharmaceuticals management was scheduled to take part in a UBS Global Biopharma Conference fireside chat on Monday, November 16, 2026, according to a Vertex Pharmaceuticals announcement published November 4. Susie Lisa, senior vice president of investor relations, and Manisha Pai, executive director of investor relations, were listed for the fireside chat.
The company scheduled the UBS session for 9:20 a.m. GMT, which corresponds to 10:20 a.m. in Berlin. Vertex said management's remarks would be available through the investor section of its website, with a replay to be archived afterward.
Investor schedule extends into November
The conference appearance forms part of a broader investor-relations schedule. Lisa and Pai are also scheduled for a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 17, at 5:00 p.m. GMT, or noon Eastern Time. Lisa and Miroslava Minkova, an executive director of investor relations, are scheduled to appear at the Evercore Healthcare Conference on December 1.
Vertex describes itself as a biotechnology company focused on medicines for serious diseases and conditions. Its approved therapies span cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, while its clinical pipeline includes programs in kidney disease, pain, endocrine disorders and other areas.
Vertex Pharmaceuticals stock traded at 493.30 euros on Lang & Schwarz at 14:11 CET on Monday, November 16, 2026.
Vertex Pharmaceuticals at a glance
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- NASDAQ ticker: VRTX
- Lang & Schwarz quote: 493.30 euros at 14:11 CET on November 16, 2026
- Sector: Biotechnology
US biotechnology stocks remain part of the broader S&P 500 market environment; see the latest S&P 500 market coverage.
